Nuvectis Pharma Inc
NVCT
Company Profile
Business description
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Contact
1 Bridge Plaza
2nd Floor, Suite 275
Fort LeeNJ07024
USAT: +1 201 614-3150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
Our analysts believe a long-term margin recovery is underway.
stocks
Two overvalued ASX shares to avoid
Both shares trade at a significant premium to our fair value.
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.00 | 13.20 | 0.15% |
| CAC 40 | 8,025.80 | 66.13 | 0.83% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 664.18 | 1.43% |
| FTSE 100 | 9,609.53 | 74.62 | 0.78% |
| HKSE | 25,894.55 | 178.05 | 0.69% |
| NASDAQ | 23,025.59 | 153.59 | 0.67% |
| Nikkei 225 | 49,245.51 | 585.99 | 1.20% |
| NZX 50 Index | 13,638.50 | 158.07 | 1.17% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,628.70 | 12.70 | 0.15% |
| SSE Composite Index | 3,870.02 | 33.26 | 0.87% |